111 related articles for article (PubMed ID: 31692911)
1. The association of family history of prostate cancer with the diagnosis of clinically significant prostate cancer in Korean population.
Park JS; Koo KC; Chung BH; Lee KS
Investig Clin Urol; 2019 Nov; 60(6):442-446. PubMed ID: 31692911
[TBL] [Abstract][Full Text] [Related]
2. Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy.
Garcia-Reyes K; Nguyen HG; Zagoria RJ; Shinohara K; Carroll PR; Behr SC; Westphalen AC
J Urol; 2018 Mar; 199(3):699-705. PubMed ID: 28941918
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
[TBL] [Abstract][Full Text] [Related]
4. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
[TBL] [Abstract][Full Text] [Related]
5. Family history and the risk of prostatic carcinoma in a high risk group of urological patients.
Aprikian AG; Bazinet M; Plante M; Meshref A; Trudel C; Aronson S; Nachabe M; Péloquin F; Déssureault J; Narod S
J Urol; 1995 Aug; 154(2 Pt 1):404-6. PubMed ID: 7541856
[TBL] [Abstract][Full Text] [Related]
6. The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study.
Lee KS; Koo KC; Chung BH
Int Urol Nephrol; 2017 Dec; 49(12):2119-2125. PubMed ID: 28905176
[TBL] [Abstract][Full Text] [Related]
7. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
van Leeuwen PJ; van den Bergh RC; Wolters T; Zhu X; Bul M; Schröder FH; Bangma CH; Roobol MJ
Can J Urol; 2011 Dec; 18(6):6018-24. PubMed ID: 22166329
[TBL] [Abstract][Full Text] [Related]
8. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
Kuru TH; Roethke MC; Seidenader J; Simpfendörfer T; Boxler S; Alammar K; Rieker P; Popeneciu VI; Roth W; Pahernik S; Schlemmer HP; Hohenfellner M; Hadaschik BA
J Urol; 2013 Oct; 190(4):1380-6. PubMed ID: 23608676
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
[TBL] [Abstract][Full Text] [Related]
10. Obesity is associated with higher risk of prostate cancer detection in a biopsy population in Korea.
Park J; Cho SY; Lee SB; Son H; Jeong H
BJU Int; 2014 Dec; 114(6):891-5. PubMed ID: 24314095
[TBL] [Abstract][Full Text] [Related]
11. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
12. Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study.
Klemann N; Røder MA; Helgstrand JT; Brasso K; Toft BG; Vainer B; Iversen P
Lancet Oncol; 2017 Feb; 18(2):221-229. PubMed ID: 28094199
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic differences between prostate cancers detected during initial and repeat transrectal ultrasound-guided biopsy in Korea.
Park DJ; Kim KH; Kwon TG; Kim CI; Park CH; Park JS; Kim DY; Kim JS; Moon KH; Lee KS
Korean J Urol; 2014 Nov; 55(11):718-24. PubMed ID: 25405013
[TBL] [Abstract][Full Text] [Related]
14. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
15. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.
Quentin M; Blondin D; Arsov C; Schimmöller L; Hiester A; Godehardt E; Albers P; Antoch G; Rabenalt R
J Urol; 2014 Nov; 192(5):1374-9. PubMed ID: 24866597
[TBL] [Abstract][Full Text] [Related]
17. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.
Kim HS; Jeon SS; Choi JD; Kim W; Han DH; Jeong BC; Seo SI; Lee KS; Lee SW; Lee HM; Choi HY
Urology; 2010 Oct; 76(4):919-22. PubMed ID: 20303152
[TBL] [Abstract][Full Text] [Related]
18. Familial prostate cancer: a different disease?
Kupelian PA; Klein EA; Witte JS; Kupelian VA; Suh JH
J Urol; 1997 Dec; 158(6):2197-201. PubMed ID: 9366343
[TBL] [Abstract][Full Text] [Related]
19. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
[TBL] [Abstract][Full Text] [Related]
20. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer.
Peters CA; Stock RG; Blacksburg SR; Stone NN
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):24-9. PubMed ID: 18692325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
